Current treatments

Improved progression-free and event-free survival in myeloma patients undergoing PBSCH receiving a cyclophosphamide + G-CSF regimen than G-CSF alone. Tanimura A et al. Int J Hematol. 2018 Jan 31. doi: 10.1007/s12185-018-2408-4. [Epub ahead of print]. Phase 1/2 Trial of Carfilzomib Plus High Dose Melphalan Preparative Regimen for Salvage AHCT Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma. Costa LJ et al. Biol Blood…

Details

Complications of myeloma and its treatments

Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis. Shah C et al. Leuk Lymphoma. 2018 Feb 21:1-13. doi: 10.1080/10428194.2018.1437269. [Epub ahead of print]. Acquired factor V deficiency in a patient with myeloma and amyloidosis. Quek JKS et al. Thromb Res. 2018 Jan 31;164:1-3. doi: 10.1016/j.thromres.2018.01.045. [Epub ahead of print]. Community-acquired respiratory infections are common in patients with non-Hodgkin lymphoma and multiple myeloma. Lavi N et…

Details

Biology and genetics

Myeloid transformation of plasma cell myeloma: molecular evidence of clonal evolution revealed by next generation sequencing. Gralewski JH et al. Diagn Pathol. 2018 Feb 20;13(1):15. doi: 10.1186/s13000-018-0692-1. The transmembrane protein TMEPAI induces myeloma cell apoptosis by promoting degradation of the c-Maf transcription factor. Du Y et al. J Biol Chem. 2018 Feb 21. pii: jbc.RA117.000972. doi: 10.1074/jbc.RA117.000972. [Epub ahead of print]. Loss of heterozygosity…

Details

Results from Phase III ALCYONE trial published

The results from the Phase III ALCYONE trial have recently been published in The New England Journal of Medicine. The study compared daratumumab (Darzalex®) in combination with bortezomib (Velcade®), melphalan and prednisone (VMP) to VMP alone in newly diagnosed myeloma patients, ineligible for a stem cell transplant. The results show that the 18-month progression-free survival…

Details

Phase III pomalidomide trial reaches primary endpoint

Celgene has announced that its Phase III trial, OPTIMISMM, has achieved its primary endpoint of improving progression-free survival (PFS) in patients with relapsed or refractory myeloma. The study compared pomalidomide (Imnovid®) in combination with bortezomib (Velcade®) and low-dose dexamethasone to bortezomib and low-dose dexamethasone in myeloma patients who had received 1 – 3 prior treatments,…

Details

Carfilzomib combinations demonstrate overall survival benefit in relapsed and refractory myeloma

Results from the Phase III ASPIRE trial show that carfilzomib (Kyprolis®) in combination with lenalidomide (Revlimid®) and dexamethasone has a significant overall survival (OS) benefit in relapsed and refractory myeloma patients. Recently published in the Journal of Clinical Oncology, the results demonstrate that patients receiving carfilzomib, lenalidomide and dexamethasone had a median OS of 48.3…

Details

Supportive treatments

Orchestration of Chemomobilization and G-CSF Administration for Successful Hematopoietic Stem Cell Collection. Kriegsmann K et al. Biol Blood Marrow Transplant. 2018 Jan 15. pii: S1083-8791(18)30022-3. doi: 10.1016/j.bbmt.2018.01.007. [Epub ahead of print]. Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update. Anderson K et al. J Clin Oncol. 2018 Jan 17:JCO2017766402. doi: 10.1200/JCO.2017.76.6402. [Epub ahead of…

Details

Related conditions

Role of IRF4 in resistance to immunomodulatory (IMid) compounds® in Waldenström’s macroglobulinemia. Bertrand E et al. Oncotarget. 2017 Dec 4;8(68):112917-112927. doi: 10.18632/oncotarget.22872. eCollection 2017 Dec 22. Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance. Kyle RA et al. N Engl J Med. 2018 Jan 18;378(3):241-249. doi: 10.1056/NEJMoa1709974. Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert…

Details

General

EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma. Tzogani K et al. Oncologist. 2018 Jan 25. pii: theoncologist.2017-0328. doi: 10.1634/theoncologist.2017-0328. [Epub ahead of print]. Immunopathogenesis and immunotherapy of multiple myeloma. Tamura H et al. Int J Hematol. 2018 Jan 24. doi: 10.1007/s12185-018-2405-7. [Epub ahead of print]. Survival of ethnic and racial minority patients with multiple myelomatreated with newer medications.…

Details

Emerging treatments

Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma(Kmm150). Jung SH et al. Biol Blood Marrow Transplant. 2018 Jan 12. pii: S1083-8791(18)30019-3. doi: 10.1016/j.bbmt.2018.01.004. [Epub ahead of print]. The role of elotuzumab in the treatment of relapsed or refractory multiple myeloma. Comeau JM et al. Am J Health Syst Pharm. 2018…

Details